重新使用抗抑郁药塞特拉林:对其抗癌机制的系统范围审查
Ciara B Blum1, McCarlie-Jayne Dohrmann1, Lucia McCarthy1
1School of Medicine and Dentistry, Griffith University, Southport, Queensland, Australia.
Pharmacology research & perspectives
|August 28, 2025
概括
塞特拉林是一种SSRI抗抑郁药,通过诱导细胞亡和破坏癌细胞代谢,显示出抗癌潜力. 其用于癌症治疗的重新用途得到了临床前数据和有利的安全性,因此需要进一步的临床试验.
科学领域:
- 癌症学
- 药理学
- 药物的转化
背景情况:
- 药物重用是发现新型癌症疗法的可行策略.
- 赛特拉林是一种选择性血清素再吸收抑制剂 (SSRI),通过影响瘤存活和抵抗途径而表现出抗癌特性.
研究的目的:
- 系统地审查关于塞特拉林抗癌机制,疗效和转化潜力的证据.
- 评估塞特拉林在调节关键癌症相关途径中的作用.
主要方法:
- 在主要数据库 (PubMed,EMBASE,Scopus,Web of Science) 进行了系统的文献搜索,遵循PRISMA-ScR指南.
- 包括体外,体内和临床研究,以及癌症类型,机制和结果的数据提取.
主要成果:
- 塞特拉林诱导细胞亡,破坏自和未折叠的蛋白质反应,并抑制血清蛋白/ 甘氨酸代谢 (SHMT).
- 它抑制瘤信号 (mTOR,TCTP) 在临床前模型中显示瘤生长抑制 (乳腺,肺,质母细胞瘤,肝脏).
- 通过克服耐药性和调节免疫反应,塞特拉林可以增强化疗,放射治疗和向治疗的疗效.
结论:
- 塞特拉林具有多重向的抗癌机制,并具有良好的安全性,支持其重用潜力.
- 主要临床前证据需要进一步的转化研究和生物标志物驱动的临床试验来确定其在瘤学中的治疗利基.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K


